4506.T लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 11:45):

Sumitomo Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally...

Stats
आज की मात्रा	1.42M
औसत मात्रा	3.35M
बाजार मूल्य	162.89B
EPS	¥0 ( 2024-01-31 )
अगली कमाई की तारीख	( ¥-323.99 ) 2024-05-13
Last Dividend	¥7.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	-0.940
ATR14	¥0.448 (0.11%)

मात्रा सहसंबंध

लंबा: 0.25 (neutral)

छोटा: 0.26 (neutral)

Signal:(64.01) Neutral

Sumitomo Pharma Co., Ltd. सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Sumitomo Pharma Co., Ltd. सहसंबंध - मुद्रा/वस्त्र

0.79
( moderate )

0.84
( strong )

-0.16
( neutral )

0.76
( moderate )

-0.05
( neutral )

0.12
( neutral )

Sumitomo Pharma Co., Ltd. वित्तीय

Annual	2022
राजस्व:	¥555.54B
सकल लाभ:	¥376.63B (67.79 %)
EPS:	¥-187.55

FY	2022
राजस्व:	¥555.54B
सकल लाभ:	¥376.63B (67.79 %)
EPS:	¥-187.55

FY	2022
राजस्व:	¥560.04B
सकल लाभ:	¥402.91B (71.94 %)
EPS:	¥102.19

FY	2021
राजस्व:	¥515.95B
सकल लाभ:	¥378.18B (73.30 %)
EPS:	¥141.50

Financial Reports:

No articles found.

Sumitomo Pharma Co., Ltd. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥14.00 (N/A)	¥0 (N/A)	¥7.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Sumitomo Pharma Co., Ltd. Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥4.75	2000-03-28
Last Dividend	¥7.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	47	--
Total Paid Out	¥382.25	--
Avg. Dividend % Per Year	0.00%	--
Score	1.47	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-07-03)

¥6.79 Estimate 1.26 %

Dividend Stability

0.10 Bad

Dividend Score

1.47

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8097.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7435.T	Ex Dividend Knight	2023-10-30	Semi-Annually	0.00%
6651.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
5981.T	Ex Dividend Junior	2024-03-28	Sporadic	0.00%
4674.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
3918.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
3150.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
2108.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
9006.T	Ex Dividend Junior	2023-09-28	Annually	0.00%
8563.T	Ex Dividend Junior	2024-03-28	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.526	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.164	1.200	-5.46	-6.56	[0 - 0.3]
returnOnEquityTTM	-0.440	1.500	-6.00	-9.00	[0.1 - 1]
payoutRatioTTM	-0.0161	-1.000	-0.161	0.161	[0 - 1]
currentRatioTTM	0.627	0.800	-1.864	-1.491	[1 - 3]
quickRatioTTM	0.333	0.800	-2.75	-2.20	[0.8 - 2.5]
cashRatioTTM	0.0866	1.500	-0.630	-0.945	[0.2 - 2]
debtRatioTTM	0.389	-1.500	3.52	-5.29	[0 - 0.6]
interestCoverageTTM	-8.87	1.000	-4.40	-4.40	[3 - 30]
operatingCashFlowPerShareTTM	-693.01	2.00	-10.00	-10.00	[0 - 30]
freeCashFlowPerShareTTM	-728.72	2.00	-10.00	-10.00	[0 - 20]
debtEquityRatioTTM	1.199	-1.500	5.20	-7.81	[0 - 2.5]
grossProfitMarginTTM	0.599	1.000	3.34	3.34	[0.2 - 0.8]
operatingProfitMarginTTM	-0.536	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.669	1.000	-4.83	-4.83	[0.2 - 2]
assetTurnoverTTM	0.312	0.800	-1.256	-1.005	[0.5 - 2]
Total Score				-5.81

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-0.938	1.000	-0.196	0	[1 - 100]
returnOnEquityTTM	-0.440	2.50	-3.86	-9.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-728.72	2.00	-10.00	-10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-693.01	2.00	-10.00	-10.00	[0 - 30]
payoutRatioTTM	-0.0161	1.500	-0.161	0.161	[0 - 1]
pegRatioTTM	-2.71	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.834	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-5.01

Sumitomo Pharma Co., Ltd.

Sumitomo Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides products for atypical antipsychotic, antiepileptic, carbapenem antibiotic, and gastrointestinal; and Anderson-Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application; Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio Company Limited; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. It also has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was founded in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.